首页 > 最新文献

Kidney Cancer最新文献

英文 中文
Clinical Trials Corner: A Promising New Drug Class in Treating Metastatic Renal Cell Carcinoma 临床试验专区:一种治疗转移性肾细胞癌的新药
IF 1.2 Q4 ONCOLOGY Pub Date : 2018-08-01 DOI: 10.3233/KCA-199001
M. Parikh
Rationale: Despite multiple studies evaluating adjuvant therapy in patients with localized RCC after nephrectomy, largely involving vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs), there remains no standard adjuvant systemic therapy that increases overall survival. While a number of adjuvant trials are underway to determine if there is a role for immune checkpoint inhibitor therapy in treatment of localized RCC, it is hypothesized that neoadjuvant PD-1 priming may be necessary to maximize effi cacy. Thus, the PROSPER RCC trial is a novel trial involving perioperative nivolumab in patients with RCC undergoing nephrectomy.
理由:尽管有多项研究评估了肾切除术后局限性肾癌患者的辅助治疗,主要涉及血管内皮生长因子(VEGF)酪氨酸激酶抑制剂(TKIs),但仍没有标准的辅助全身治疗来提高总生存率。虽然许多辅助试验正在进行中,以确定免疫检查点抑制剂治疗在局部RCC治疗中的作用,但假设新辅助PD-1启动可能是最大化疗效所必需的。因此,PROSPER RCC试验是一项新的试验,涉及接受肾切除术的RCC患者围手术期的纳伏单抗。
{"title":"Clinical Trials Corner: A Promising New Drug Class in Treating Metastatic Renal Cell Carcinoma","authors":"M. Parikh","doi":"10.3233/KCA-199001","DOIUrl":"https://doi.org/10.3233/KCA-199001","url":null,"abstract":"Rationale: Despite multiple studies evaluating adjuvant therapy in patients with localized RCC after nephrectomy, largely involving vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs), there remains no standard adjuvant systemic therapy that increases overall survival. While a number of adjuvant trials are underway to determine if there is a role for immune checkpoint inhibitor therapy in treatment of localized RCC, it is hypothesized that neoadjuvant PD-1 priming may be necessary to maximize effi cacy. Thus, the PROSPER RCC trial is a novel trial involving perioperative nivolumab in patients with RCC undergoing nephrectomy.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/KCA-199001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44490919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intensity Modulated Radiotherapy is a Well-Tolerated and Effective Treatment for the Long-Term Control of Intra-Abdominal and Retroperitoneal Oligometastatic Renal Cell Cancer 调强放射治疗是一种耐受性好且有效的治疗方法,可长期控制腹膜内和腹膜后少转移肾细胞癌症
IF 1.2 Q4 ONCOLOGY Pub Date : 2018-08-01 DOI: 10.3233/KCA-170025
I. Maund, A. B. Al-Naeeb, S. Welsh, T. Eisen, K. Fife
Background: The use of conventionally fractionated intensity modulated radiotherapy (IMRT) in the management of oligometastatic renal cell carcinoma (RCC) is currently poorly characterised in the literature. Objective: To evaluate the safety and effectiveness of IMRT for intraabdominal and retroperitoneal RCC oligometastases. Methods: Retrospective analysis of 14 patients with oligometastatic RCC treated with IMRT with the aim of inducing longterm control. Indications for radiotherapy included bleeding abdominal mass (5 patients), solitary renal bed recurrence (5 patients) and isolated, asymptomatic pancreatic mass (4 patients). The prescribed radiotherapy dose was 50 Gray in 20 to 25 fractions. Patients were followed up long-term using regular cross-sectional imaging and clinical review to assess local and distant disease control and treatment related toxicity. Results: At median follow up of 33.5 (6–68) months, 12 patients remain alive (86%), of whom 11 (92%) have no evidence of local recurrence. Six patients (43%) developed further metastatic disease, of whom 4 (67%) received systemic treatment. Median duration of local control was 33.5 months, and 1and 3-year overall survival (OS) was 92.9% and 85.7% respectively. No treatment-related toxicities ≥ grade 3 and no long-term sequelae were observed. Conclusions: IMRT to intra-abdominal and retroperitoneal metastasis in oligo-metastatic RCC can be delivered safely, provide durable responses and excellent longer-term survival if given to a sufficiently high dose over a conventionally fractionated course. Our study is the first to date with long-term follow up to evaluate the role of IMRT in such cases and has important implications for treatment of oligometastatic RCC.
背景:传统分级调强放射治疗(IMRT)在治疗少转移性肾细胞癌(RCC)中的应用目前在文献中描述不多。目的:评价IMRT治疗腹膜内和腹膜后肾细胞癌少转移瘤的安全性和有效性。方法:回顾性分析14例接受IMRT治疗的低转移性RCC患者,以期获得长期控制。放射治疗的适应症包括腹部出血性肿块(5名患者)、孤立性肾床复发(5名)和孤立性无症状胰腺肿块(4名患者)。规定的放射治疗剂量为50格雷,分为20至25个部分。使用定期横断面成像和临床回顾对患者进行长期随访,以评估局部和远处的疾病控制和治疗相关毒性。结果:在中位随访33.5(6-68)个月时,12名患者(86%)仍然存活,其中11名患者(92%)没有局部复发的证据。6名患者(43%)出现进一步的转移性疾病,其中4名(67%)接受了全身治疗。局部控制的中位持续时间为33.5个月,1年和3年总生存率(OS)分别为92.9%和85.7%。未观察到治疗相关毒性≥3级,也未观察到长期后遗症。结论:如果在常规分期过程中给予足够高的剂量,IMRT可以安全地治疗少转移性RCC的腹腔内和腹膜后转移,提供持久的反应和良好的长期生存率。我们的研究是迄今为止第一个长期随访评估IMRT在此类病例中的作用的研究,对治疗少转移性RCC具有重要意义。
{"title":"Intensity Modulated Radiotherapy is a Well-Tolerated and Effective Treatment for the Long-Term Control of Intra-Abdominal and Retroperitoneal Oligometastatic Renal Cell Cancer","authors":"I. Maund, A. B. Al-Naeeb, S. Welsh, T. Eisen, K. Fife","doi":"10.3233/KCA-170025","DOIUrl":"https://doi.org/10.3233/KCA-170025","url":null,"abstract":"Background: The use of conventionally fractionated intensity modulated radiotherapy (IMRT) in the management of oligometastatic renal cell carcinoma (RCC) is currently poorly characterised in the literature. Objective: To evaluate the safety and effectiveness of IMRT for intraabdominal and retroperitoneal RCC oligometastases. Methods: Retrospective analysis of 14 patients with oligometastatic RCC treated with IMRT with the aim of inducing longterm control. Indications for radiotherapy included bleeding abdominal mass (5 patients), solitary renal bed recurrence (5 patients) and isolated, asymptomatic pancreatic mass (4 patients). The prescribed radiotherapy dose was 50 Gray in 20 to 25 fractions. Patients were followed up long-term using regular cross-sectional imaging and clinical review to assess local and distant disease control and treatment related toxicity. Results: At median follow up of 33.5 (6–68) months, 12 patients remain alive (86%), of whom 11 (92%) have no evidence of local recurrence. Six patients (43%) developed further metastatic disease, of whom 4 (67%) received systemic treatment. Median duration of local control was 33.5 months, and 1and 3-year overall survival (OS) was 92.9% and 85.7% respectively. No treatment-related toxicities ≥ grade 3 and no long-term sequelae were observed. Conclusions: IMRT to intra-abdominal and retroperitoneal metastasis in oligo-metastatic RCC can be delivered safely, provide durable responses and excellent longer-term survival if given to a sufficiently high dose over a conventionally fractionated course. Our study is the first to date with long-term follow up to evaluate the role of IMRT in such cases and has important implications for treatment of oligometastatic RCC.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/KCA-170025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42948199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional Predictors of Perioperative Complications and Mortality Following Nephrectomy for Renal Malignancies: A Population-Based Analysis 肾恶性肿瘤肾切除术后围手术期并发症和死亡率的营养预测因素:基于人群的分析
IF 1.2 Q4 ONCOLOGY Pub Date : 2018-08-01 DOI: 10.3233/KCA-180036
Karan Arora, K. Hanson, E. Habermann, M. Tollefson, S. Psutka
Introduction and Objective: Conflicting data exists regarding the impact of body mass index (BMI) on postoperative outcomes following surgery for renal malignancies (RM). Herein, we investigated associations between obesity, hypoalbuminemia, and/or significant weight loss in the preoperative period, and risk complications and mortality within 30 days of radical (RN) or partial nephrectomy (PN). Materials and Methods: Review of the American College of Surgeons National Surgical Quality Improvement Program database identified 8,618 patients treated with PN or RN for RM between 2005 and 2012. Univariate and multivariable logistic regression models were developed to assess associations between hypoalbuminemia (<3.5 g/dl), >10% weight loss within 6 months of surgery, obesity (BMI >30 kg/m2), and 30-day major complications and mortality. Results: Median BMI was 29.2 kg/m2 with 24.9%, 11.9%, and 8.2% having class I, II, and III obesity, respectively. Weight loss of >10% was observed in 2.6% and 15.4% had preoperative albumin<3.5 g/dl. There were 1,802 complications (20.9%) and 88 deaths within 30 days (1.0%). On multivariable analysis, BMI ≥40 kg/m2 (OR 1.3, p = 0.04), >10% weight loss (OR 1.9, p < 0.001) and hypoalbuminemia (OR 1.5, p < 0.001) were independently associated with 30-day complications, while only >10% weight loss was independently associated with 30-day mortality (OR 2.4, p = 0.03). Conclusions: Extreme obesity, hypoalbuminemia, and significant weight loss were independently associated with risk of significant complications following PN or RN while only significant preoperative weight loss was associated with early mortality, underscoring the need to further understand the utility of moderating these risk factors in the perioperative period.
引言和目的:关于肾脏恶性肿瘤(RM)手术后体重指数(BMI)对术后结果的影响,存在相互矛盾的数据。在此,我们研究了肥胖、低白蛋白血症和/或术前显著体重减轻与根治性(RN)或部分肾切除术(PN)30天内的风险并发症和死亡率之间的关系。材料和方法:对美国外科医生学会国家外科质量改进计划数据库的审查确定,2005年至2012年间,8618名接受PN或RN RM治疗的患者。开发了单变量和多变量逻辑回归模型,以评估低白蛋白血症(手术后6个月内体重减轻10%)、肥胖(BMI>30 kg/m2)和30天主要并发症与死亡率之间的关系。结果:中位BMI为29.2 kg/m2,其中I、II和III级肥胖分别占24.9%、11.9%和8.2%。2.6%的患者体重减轻>10%,15.4%的患者术前有白蛋白。10%的体重减轻(OR 1.9,p<0.001)和低白蛋白血症(OR 1.5,p<0.001)与30天并发症独立相关,而只有>10%的体重减轻与30天死亡率独立相关(OR 2.4,p=0.03),和显著的体重减轻与PN或RN后出现显著并发症的风险独立相关,而只有显著的术前体重减轻与早期死亡率相关,强调需要进一步了解在围手术期调节这些风险因素的效用。
{"title":"Nutritional Predictors of Perioperative Complications and Mortality Following Nephrectomy for Renal Malignancies: A Population-Based Analysis","authors":"Karan Arora, K. Hanson, E. Habermann, M. Tollefson, S. Psutka","doi":"10.3233/KCA-180036","DOIUrl":"https://doi.org/10.3233/KCA-180036","url":null,"abstract":"Introduction and Objective: Conflicting data exists regarding the impact of body mass index (BMI) on postoperative outcomes following surgery for renal malignancies (RM). Herein, we investigated associations between obesity, hypoalbuminemia, and/or significant weight loss in the preoperative period, and risk complications and mortality within 30 days of radical (RN) or partial nephrectomy (PN). Materials and Methods: Review of the American College of Surgeons National Surgical Quality Improvement Program database identified 8,618 patients treated with PN or RN for RM between 2005 and 2012. Univariate and multivariable logistic regression models were developed to assess associations between hypoalbuminemia (<3.5 g/dl), >10% weight loss within 6 months of surgery, obesity (BMI >30 kg/m2), and 30-day major complications and mortality. Results: Median BMI was 29.2 kg/m2 with 24.9%, 11.9%, and 8.2% having class I, II, and III obesity, respectively. Weight loss of >10% was observed in 2.6% and 15.4% had preoperative albumin<3.5 g/dl. There were 1,802 complications (20.9%) and 88 deaths within 30 days (1.0%). On multivariable analysis, BMI ≥40 kg/m2 (OR 1.3, p = 0.04), >10% weight loss (OR 1.9, p < 0.001) and hypoalbuminemia (OR 1.5, p < 0.001) were independently associated with 30-day complications, while only >10% weight loss was independently associated with 30-day mortality (OR 2.4, p = 0.03). Conclusions: Extreme obesity, hypoalbuminemia, and significant weight loss were independently associated with risk of significant complications following PN or RN while only significant preoperative weight loss was associated with early mortality, underscoring the need to further understand the utility of moderating these risk factors in the perioperative period.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/KCA-180036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42997182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Partial Nephrectomy is the Surgical Treatment of Choice for (Most) Complex Localized Renal Tumors 肾部分切除术是(大多数)复杂局限性肾肿瘤的手术治疗选择
IF 1.2 Q4 ONCOLOGY Pub Date : 2018-08-01 DOI: 10.3233/KCA-180039
A. Herlemann, A. Herlemann, A. Odisho, S. Porten
The decision to undergo partial nephrectomy (PN) versus radical nephrectomy (RN) for a localized renal mass should take various factors into consideration, including tumor characteristics, patient’s health status and preference, and risks and benefits of these each approach. PN represents a suitable surgical approach for small renal tumors in favorable locations. It may also better preserve long-term renal function, particularly in patients who may need surgery for a contralateral kidney mass or have preexisting chronic kidney disease. Conversely, RN may be preferred in elderly patients with severe (non-renal related) comorbidities, in patients with an anatomically challenging tumor location, or for larger or locally advanced masses. The presentation and management of renal tumors has changed substantially during the last few decades. The increasing use and quality of crosssectional imaging has been associated with increased incidence, earlier detection and improved staging of renal masses [12]. Most kidney tumors are now diagnosed incidentally in asymptomatic patients [3]. In a recent study by Welch et al. examining a large cohort of Medicare beneficiaries, increase rates of computed tomography (CT) imaging was associated with
对于局限性肾脏肿块,决定接受部分肾切除术(PN)还是根治性肾切除术(RN)应考虑各种因素,包括肿瘤特征、患者的健康状况和偏好,以及每种方法的风险和益处。PN代表了在有利位置治疗小型肾肿瘤的合适手术方法。它还可以更好地保持长期肾功能,特别是对于可能需要对侧肾肿块手术或已有慢性肾脏疾病的患者。相反,RN可能更适合患有严重(非肾脏相关)合并症的老年患者、具有解剖挑战性肿瘤位置的患者,或较大或局部晚期肿块的患者。在过去的几十年里,肾脏肿瘤的表现和治疗发生了很大的变化。横断面成像的使用和质量的提高与肾脏肿块的发病率增加、早期发现和分期改善有关[12]。大多数肾脏肿瘤现在都是在无症状患者中偶然诊断出来的[3]。在Welch等人最近的一项研究中,对一大群联邦医疗保险受益人进行了检查,计算机断层扫描(CT)成像率的增加与
{"title":"Partial Nephrectomy is the Surgical Treatment of Choice for (Most) Complex Localized Renal Tumors","authors":"A. Herlemann, A. Herlemann, A. Odisho, S. Porten","doi":"10.3233/KCA-180039","DOIUrl":"https://doi.org/10.3233/KCA-180039","url":null,"abstract":"The decision to undergo partial nephrectomy (PN) versus radical nephrectomy (RN) for a localized renal mass should take various factors into consideration, including tumor characteristics, patient’s health status and preference, and risks and benefits of these each approach. PN represents a suitable surgical approach for small renal tumors in favorable locations. It may also better preserve long-term renal function, particularly in patients who may need surgery for a contralateral kidney mass or have preexisting chronic kidney disease. Conversely, RN may be preferred in elderly patients with severe (non-renal related) comorbidities, in patients with an anatomically challenging tumor location, or for larger or locally advanced masses. The presentation and management of renal tumors has changed substantially during the last few decades. The increasing use and quality of crosssectional imaging has been associated with increased incidence, earlier detection and improved staging of renal masses [12]. Most kidney tumors are now diagnosed incidentally in asymptomatic patients [3]. In a recent study by Welch et al. examining a large cohort of Medicare beneficiaries, increase rates of computed tomography (CT) imaging was associated with","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/KCA-180039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48821343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal First-Line Treatment of Metastatic Renal-Cell Carcinoma: A Network Meta-Analysis 转移性肾细胞癌的最佳一线治疗:网络荟萃分析
IF 1.2 Q4 ONCOLOGY Pub Date : 2018-08-01 DOI: 10.3233/KCA-180032
A. Hahn, P. Hale, B. Maughan, B. Haaland, N. Agarwal
Background: First-line treatment of metastatic renal cell carcinoma (mRCC) has incrementally evolved over the past decade. Most recently, promising clinical trials for first-line cabozantinib, nivolumab plus ipilimumab, and bevacizumab plus atezolizumab were reported. However, the comparator arm in all of these trials was sunitinib, so no head-to-head comparison exists for contemporary first-line treatments. Objective: To provide an indirect comparison of first-line treatments for mRCC that are currently approved or likely soon
背景:转移性肾细胞癌(mRCC)的一线治疗在过去十年中逐渐发展。最近,有报道称,一线卡博替尼、尼沃单抗加易普利单抗和贝伐单抗加atezolizumab的临床试验前景看好。然而,所有这些试验中的对照组都是舒尼替尼,因此当代一线治疗不存在正面比较。目的:对目前批准或可能很快批准的mRCC一线治疗方法进行间接比较
{"title":"Optimal First-Line Treatment of Metastatic Renal-Cell Carcinoma: A Network Meta-Analysis","authors":"A. Hahn, P. Hale, B. Maughan, B. Haaland, N. Agarwal","doi":"10.3233/KCA-180032","DOIUrl":"https://doi.org/10.3233/KCA-180032","url":null,"abstract":"Background: First-line treatment of metastatic renal cell carcinoma (mRCC) has incrementally evolved over the past decade. Most recently, promising clinical trials for first-line cabozantinib, nivolumab plus ipilimumab, and bevacizumab plus atezolizumab were reported. However, the comparator arm in all of these trials was sunitinib, so no head-to-head comparison exists for contemporary first-line treatments. Objective: To provide an indirect comparison of first-line treatments for mRCC that are currently approved or likely soon","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/KCA-180032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44203436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Abstracts from the Sixteenth International Kidney Cancer Symposium, 2nd-3rd November 2017, Miami, Florida 第十六届国际肾癌研讨会,2017年11月2 -3日,美国佛罗里达州迈阿密
IF 1.2 Q4 ONCOLOGY Pub Date : 2018-03-02 DOI: 10.3233/KCA-189001
Pedro, Crivelaro, L. Doro
s from the Sixteenth International Kidney Cancer Symposium, 2nd-3rd November 2017,
来自第十六届癌症国际研讨会,2017年11月2日至3日,
{"title":"Abstracts from the Sixteenth International Kidney Cancer Symposium, 2nd-3rd November 2017, Miami, Florida","authors":"Pedro, Crivelaro, L. Doro","doi":"10.3233/KCA-189001","DOIUrl":"https://doi.org/10.3233/KCA-189001","url":null,"abstract":"s from the Sixteenth International Kidney Cancer Symposium, 2nd-3rd November 2017,","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":"2 1","pages":"I - S50"},"PeriodicalIF":1.2,"publicationDate":"2018-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/KCA-189001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45396787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Kidney Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1